Enterprise Value
898.6M
Cash
185M
Avg Qtr Burn
N/A
Short % of Float
13.04%
Insider Ownership
4.68%
Institutional Own.
96.35%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ARCALYST (Rilonacept) (IL-1α & IL-1β) Details Recurrent Pericarditis | Approved Quarterly sales | |
Vixarelimab (OSMRβ) (KPL-716) Details Skin disease/disorder, Prurigo nodularis | Phase 2b Update | |
KPL-404 (CD40) Details Autoimmune disease, Rheumatoid arthritis | Phase 2 Data readout | |
Mavrilimumab (GM-CSFRa) Details Inflammatory disease, Giant cell arteritis | Failed Discontinued | |
Mavrilimumab (GM-CSFRa) Details COVID-19, Pneumonia | Failed Discontinued |